Ocular Therapeutix (OCUL) Current Deferred Revenue (2013 - 2026)

Ocular Therapeutix's Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 21775.0% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (up 21775.0% YoY), while the FY2025 annual figure was $14.0 million, up 10837.5% from the prior year.
• Current Deferred Revenue was $14.0 million for Q1 2026 at Ocular Therapeutix, roughly flat from $14.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $14.6 million in Q2 2023 to a low of $64000.0 in Q1 2025.
• Historically, Current Deferred Revenue has averaged $8.5 million across 5 years, with a median of $14.0 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue tumbled 99.11% in 2024, then jumped 21775.0% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $14.0 million in 2022, then advanced by 3.06% to $14.4 million in 2023, then sank by 99.11% to $128000.0 in 2024, then surged by 10837.5% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $14.0 million (Q1 2026), $14.0 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.